Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study
Related Posts
Modiri O, Ebriani J, Jairath N, Lewin J. AI-Assisted Billing in Dermatologic Surgery: Evaluating ChatGPT's and Gemini's Accuracy in CPT Code Assignment. Dermatol Surg. 2025[...]
Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of[...]
Bunick CG, Armstrong AW, Grada A, Soliman AM, Li C, Bristow CC, Khan IA, Lipiszko D, Silverberg JI, Issa NT, Mostaghimi A. The Epidemiology of[...]